Testing an Educational Tool for Melanoma Patients With Autoimmune Disease
Tests an educational tool for adults with melanoma and autoimmune disease considering immunotherapy.
Plain-language title generated from the registry record
Registry title: Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Key facts
- Where
- Houston, United StatesSee the site
Where in United States
- M D Anderson Cancer CenterHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- M.D. Anderson Cancer Center
- Trial code
- NCT04751396
- Record updated
- 20 May 2026
- Original description
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.Read full original descriptionShow less
Testing of an Educational Tool for Patients With Melanoma and Concomitant Autoimmune Disease Who Are Candidates for Adjuvant Therapy With Immune Checkpoint Inhibitors: Acceptability and Usability With Patients and Providers
This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.
Inclusion: Diagnosis of melanoma; Diagnosis of pre-existing autoimmune disease; Inflammatory bowel disease; Diagnosis of Crohn's disease or ulcerative colitis by a gastroenterologist; For ulcerative colitis, proof of chronic changes over time (i.e., 6 months) and signs of inflammation histologically; Treatment with aminosalicylates, corticosteroids, thiopurines, or immune modifiers (e.g., calcineurin inhibitors, methotrexate, adhesion molecule antagonists); Rheumatoid arthritis; Diagnosis of rheumatoid arthritis by a rheumatologist; Treatment with traditional disease-modifying antirheumatic drugs (e.g., methotrexate, sulfasalazine, hydroxychloroquine) or targeted therapy; Systemic lupus erythematosus; Diagnosis of systemic lupus erythematosus by a rheumatologist; Psoriasis; Diagnosis of psoriasis by a dermatologist; Treatment with corticosteroids, vitamin D analogs, anthralin, topical retinoids, calcineurin inhibitors, salicylic acid, coal tar, or moisturizers; light therapy, including sunlight, ultraviolet B (UVB) phototherapy, narrowband UVB therapy, Goeckerman therapy, photochemotherapy, excimer laser, or pulsed dye laser; or systemic medications, including retinoids, methotrexate, cyclosporine, hydroxyurea, or thioguanine or targeted therapies; Spondyloarthropathies; Diagnosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis, or enteropathic arthritis/spondylitis by a rheumatologist; Treatment with disease-modifying antirheumatic drugs (e.g., sulfasalazine) or targeted therapy; Age of 18 years or older; Patients whose physicians had recommended they begin using any of the currently available immune checkpoint inhibitors or people who are in the midst of or have already made the decision on whether or not start an immune checkpoint inhibitor; E-mail access and computer with Internet access or telephone; Ability to communicate in English or Spanish; CLINICIAN; Prescribed immune checkpoint inhibitors; Are providing care for patients with melanoma; In the clinics at MD Anderson.